Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's in...
Australian cancer specialists may hold key to next advancement in ovarian cancer treatment
SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Associate Professor Jim Coward, an oncologist at Icon Cancer Care in South Brisbane, is leading the fi...
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
SYDNEY, Aug. 22, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc inOcto...
Board Review of Business Operations and Governance
SYDNEY, Aug. 14, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appo...
Progress Update on Cantrixil(TM) (TRXE-002-1) Development
SYDNEY, Aug. 7, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Phase I Clinical Trial in Ovarian Cancer Pro...
Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure
- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC position Novogen for success in these activities - Dr David Brown, Chief Scientific Officer...
Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program
SYDNEY, March 6, 2017 /PRNewswire/ -- * Grant is provided under Cooperative Research Centre Project (CRC-P) scheme and provides up toA$3 million in cash over three years * Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new ...
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has fully-acquired Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. The transaction includes ...
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma
SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialise GDC-0084, a small ...
Conversion of Convertible Notes
SYDNEY, Sept. 14, 2016 /PRNewswire/ -- On 19 April 2013, the shareholders of Novogen Limited approved the issue of 60,000,000 convertible securities, with a face value of$1.5M, to the former securities holders of Triaxial Pharmaceuticals Pty Ltd. The conversions of the convertible notes are cont...
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer
SYDNEY, Sept. 12, 2016 /PRNewswire/ -- * Cantrixil (TRX-E-002-1) is Novogen's lead development candidate, and is being developed as an intraperitoneal therapy for patients with ovarian cancer * Investigational New Drug (IND) application is the key regulatory filing to initiate clinical trial...
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
SYDNEY, Aug. 11, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002...
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant
SYDNEY, June 14, 2016 /PRNewswire/ -- US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted inAustralia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507). Novogen North Am...
Novogen Provides Update On Development Of Cantrixil
SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian canc...
Novogen Receives R&D Tax Incentive Cash Refund
SYDNEY, March 17, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of$2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending30 June 2015. This wi...
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant
SYDNEY, Feb. 19, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted inAustralia. This patent provides full prot...
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
SYDNEY, Feb. 5, 2016 /PRNewswire/ -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, MrJohn O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James G...
Novogen Appoints Dr James Garner as Chief Executive Officer
SYDNEY, Dec. 10, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of D...
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial
SYDNEY, Nov. 24, 2015 /PRNewswire/ -- * Novogen engages Novotech as CRO for upcoming Phase 1 clinical study * Cantrixil Phase 1 clinical trial to be conducted in patients with refractory/recurrent peritoneal malignancies with malignant ascites, including ovarian cancer US-Australian drug dis...
